Exscientia, founded in 2012 in Oxford, UK, is a trailblazing AI-driven drug discovery platform for precision medicine that leverages artificial intelligence to revolutionize pharmaceutical development. Acquired by Recursion Pharmaceuticals in November 2024, Exscientia combines AI, automation, and patient-centric data to design safer, more effective drugs faster. With over $450 million in milestone payments and a pipeline of more than 10 clinical and preclinical programs, patient-first AI for drug development has delivered the first three AI-designed drugs to clinical trials, achieving 10 times productivity gains. Trusted by partners like Sanofi and Bristol Myers Squibb, Exscientia operates globally, focusing on oncology and beyond.